Publications / Posters :: ContraFect Corporation (CFRX)

Publications / Posters

Technology

Home
Technology
Publications / Posters

Bacteriophage Lysin CF-301: a Potent Anti-Staphylococcal Biofilm Agent

Antimicrob. Agents Chemother (2017) 61 (7) e02666-16

Combination Therapy with Lysin CF-301 and Antibiotic Is Superior to Antibiotic Alone for Treating Methicillin-Resistant Staphylococcus aureus-Induced Murine Bacteremia

Journal of Infectious Diseases, (2014) 209 (9): 1469-1478.

Lysin CF-370 Exhibits Broad Spectrum Antimicrobial Activity Against Gram-Negative (GN) ESKAPE Pathogens

Presented at World Microbe, June 2021

Lysin CF-370 In Vivo Efficacy Against a Carbapenem-Resistant Pseudomonas aeruginosa in a Rabbit Infective Endocarditis Model

Presented at World Microbe, June 2021

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

PK-PD Relationship and PK Driver of Efficacy of the Novel Antibacterial Lysin Exebacase (CF-301) in Pre-Clinical Models

Presented at ID Week 2019, October 4, 2019

Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Exebacase (Lysin CF-301) Activity Against Staphylococcus aureus (S. aureus) Isolates from Bacteremic Patients Enrolled in a Phase 2 Study (CF-301-102)

Presented at ID Week 2019, October 3, 2019

Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires

Activity of Exebacase (CF-301) Against Methicillin-Resistant Staphylococcus aureus (MRSA) Biofilms on Orthopedic Kirschner Wires

Presented at ID Week 2019, October 3, 2019

Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)

Impact of Dose-Administration Strategies of the Antistaphylococcal Lysin Exebacase, (CF-301), in Addition to Daptomycin (DAP) in an Experimental Infective Endocarditis (IE) Model due to Methicillin-Resistant Staphylococcus aureus (MRSA)

Presented at ID Week 2019, October 3, 2019

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Amurin Peptide App2-M1 Eradicates Stenotrophomonas maltophilia Biofilms Formed on Hemodialysis Catheters in the Setting of Human Infection

Presented at ASM-ESCMID 2019, September 4, 2019

CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis

CF-301 and Daptomycin Treatment of Methicillin-Resistant Staphylococcus aureus Associated Experimental Osteomyelitis

Presented at ASM 2019, June 23, 2019

Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant

Lysins Exhibit Potent Bactericidal Activity, Synergy and Antibiofilm Effects against Pseudomonas aeruginosa in Human Serum and Pulmonary Surfactant

Presented at ASM 2019, June 23, 2019

Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model

Bacteriophage Lysin CF-301 (Exebacase) in Addition to Daptomycin in a Simulated Endocardial Vegetation (SEV) PK/PD Model

Presented at ASM 2019, June 23, 2019

« Previous
1
2
3
4
5
6
7
Next »